Anti-FOXO3 monoclonal antibody, clone 2C22

Oncogenic anaplastic lymphoma kinase (ALK) is one of the few druggable targets in neuroblastoma, and therapy resistance to ALK-targeting tyrosine kinase inhibitors (TKIs) comprises an inevitable clinical challenge. Therefore, a better understanding of the oncogenic signaling network rewiring driven by ALK is necessary to improve and guide future therapies. Here, we performed quantitative mass spectrometry-based proteomics on neuroblastoma cells treated with one of three clinically relevant ALK TKIs (crizotinib, LDK378, or lorlatinib) or an experimentally used ALK TKI (TAE684) to unravel aberrant ALK signaling pathways. Our integrated proximal proteomics (IPP) strategy included multiple signaling layers, such as the ALK interactome, phosphotyrosine interactome, phosphoproteome, and proteome. We identified the signaling adaptor protein IRS2 (insulin receptor substrate 2) as a major ALK target and an ALK TKI-sensitive signaling node in neuroblastoma cells driven by oncogenic ALK. TKI treatment decreased the recruitment of IRS2 to ALK and reduced the tyrosine phosphorylation of IRS2. Furthermore, siRNA-mediated depletion of ALK or IRS2 decreased the phosphorylation of the survival-promoting kinase Akt and of a downstream target, the transcription factor FoxO3, and reduced the viability of three ALK-driven neuroblastoma cell lines. Collectively, our IPP analysis provides insight into the proximal architecture of oncogenic ALK signaling by revealing IRS2 as an adaptor protein that links ALK to neuroblastoma cell survival through the Akt-FoxO3 signaling axis.

Many metabolic syndromes lead to energetic disturbs which ends to an intense catabolic state. The branched-chain amino acid leucine shows very positive effects on muscle protein metabolism. However, it is still not clear how leucine acts improving the protein turnover. This study aimed to evaluate in vitro the effects of leucine supplementation in minimising the signalling pathway of protein degradation when mTOR was inhibited. Our studies were conducted in murine C2C12 myotubes exposed to 2mM leucine or 2mM isoleucine in control situation and compared to the inhibition of mTOR by rapamycin. Then, the expression of proteins related to protein synthesis and degradation signalling pathway was obtained by Western Blot. At this concentration, the leucine was sufficient to maintain the expression of proteins evaluated as in control situation. However, when the cells were exposed to rapamycin (80nM), leucine inhibited the expression of SMAD and FoxO3a, showing that leucine was able to modulate the degradation pathway when protein synthesis is compromised. Furthermore, leucine had no effect in modifying the expression of subunits of ubiquitin-proteasome system, showing that leucine had no direct effect in ubiquitin-proteasome system, but acted leading to the phosphorylation of SMAD and FoxO3, which inhibited the activity of transcriptional of these proteins. No similar results were observed in cells exposed to isoleucine under the same experimental protocol, likely showing that leucine has specific action over another branched-chain amino acids. In conclusion, the present study shows that leucine can modulate degradation pathways even under inhibition of mTOR by rapamycin.